(56 days)
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
·Proton density (PD) (also called hydrogen density)
- ·Spin-lattice relaxation time (T1)
- ·Spin-spin relaxation time (T2)
·Flow dynamics
·Chemical Shift
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
The Vantage Orian (Model MRT-1550) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Orian uses 1.4 m short and 3.8 tons light weight magnet. It includes the Pianissimo™ technology (scan noise reduction technology). The design of the gradient coil and the WB coil of the Vantage Orian 1.5T provides the maximum field of view of 55 x 50 cm. The Model MRT-1550/AC, AD, AG, AH includes the standard gradient system and Model MRT-1550/AK, AL, AO, AP includes the XGO gradient system.
This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body. The Vantage Orian MRI System is comparable to the current 1.5T Vantage Orian MRI System (K193097), cleared July 14th, 2020 with the following modifications.
The provided text describes a 510(k) premarket notification for a modified MRI device, the Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR. The submission primarily details software functionalities added to an already cleared predicate device (V6.0 version). While it mentions image quality testing, it does not present specific acceptance criteria or a detailed study proving the device meets those criteria in a format applicable to evaluating AI/algorithm performance.
Specifically, the document does not contain the detailed information required for the requested output about AI/algorithm acceptance criteria and performance study, such as:
- A table of acceptance criteria with numerical performance metrics (e.g., sensitivity, specificity, AUC).
- Sample sizes used for test sets specifically for AI performance evaluation.
- Data provenance (country of origin, retrospective/prospective) for AI testing.
- Number and qualifications of experts for ground truth establishment.
- Adjudication methods.
- MRMC comparative effectiveness study details.
- Standalone algorithm performance metrics.
- Type of ground truth (e.g., pathology, outcomes data).
- Training set sample size and ground truth establishment for the training set.
The document discusses imaging performance parameters and states "image quality testing was completed which demonstrated that the subject device meets predetermined acceptance criteria." However, it only provides a high-level summary of this testing:
- Testing Information Present:
- "MR image quality metrics were performed, utilizing volunteer images, to assess 3D FAST sequences and 3D Compressed SPEEDER acceleration sequences."
- "Representative images, reviewed by American Board Certified Radiologists and American Board Certified Cardiologists with MR certification, were obtained using the subject device."
- "Reviewers provided detailed assessments of overall image noise, image sharpness, image degradation, image artifacts, diagnostic confidence, contrast, lesion/pathology conspicuity, and clinical utility."
- "It was confirmed that 3D FAST and 3D Compressed SPEEDER images were of diagnostic quality."
This information focuses on the qualitative assessment of diagnostic image quality by experts for new imaging sequences or acceleration techniques (which are software functionalities, but not necessarily an AI diagnostic algorithm that outputs a decision or risk score). There is no mention of a specific AI algorithm for diagnosis or detection requiring the type of performance metrics typically associated with AI/algorithmic acceptance criteria (e.g., those found in a diagnostic AI device).
Therefore, I cannot fulfill the request with the provided input text as the necessary details for a robust AI performance study are absent. The document describes modifications to an MRI system itself and its imaging sequences, rather than the evaluation of a distinct AI diagnostic algorithm with specific performance targets.
{0}------------------------------------------------
December 2, 2020
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is a blue square with the letters "FDA" in white, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue.
Canon Medical Systems Corporation % Ms. Janine F. Reyes Manager, Regulatory Affairs Canon Medical Systems USA 2441 Michelle Drive TUSTIN CA 92780
Re: K203053
Trade/Device Name: Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: Class II Product Code: LNH Dated: October 2, 2020 Received: October 7, 2020
Dear Ms. Reyes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2020 See PRA Statement below.
510(k) Number (if known)
Device Name
Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
Indications for Use (Describe)
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
·Proton density (PD) (also called hydrogen density)
- ·Spin-lattice relaxation time (T1)
- ·Spin-spin relaxation time (T2)
·Flow dynamics
·Chemical Shift
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| × Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Image /page/3/Picture/3 description: The image shows the logo for Canon Medical Systems USA, INC. The word "Canon" is in large, bold, red letters. Below it, in smaller black letters, is the text "CANON MEDICAL SYSTEMS USA, INC."
Made For life
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92
1. CLASSIFICATION and DEVICE NAME
| Classification Name: | Magnetic Resonance Diagnostic Device |
|---|---|
| Regulation Number: | 90-LNH (Per 21 CFR § 892.1000) |
| Trade Proprietary Name: | Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE ReconstructionProcessing Unit for MR |
| Model Number: | MRT-1550 |
2. SUBMITTER'S NAME
Canon Medical Systems Corporation 1385 Shimoishigami Otawara-Shi, Tochigi-ken, Japan 324-8550
3. OFFICIAL CORRESPONDENT
Naofumi Watanabe Senior Manager, Regulatory Affairs and Vigilance Canon Medical Systems Corporation
4. CONTACT PERSON, U.S. AGENT and ADDRESS
Contact Person
Janine F. Reyes Manager, Regulatory Affairs Canon Medical Systems USA, Inc. 2441 Michelle Drive, Tustin, CA 92780 Phone: (714) 669-7853 Fax: (714) 730-1310 E-mail: jfreyes@us.medical.canon
Official Correspondent/U.S. Agent
Paul Biggins Senior Director, Regulatory Affairs Canon Medical Systems USA, Inc. 2441 Michelle Drive, Tustin, CA 92780 Phone: (714) 730-7808 Fax: (714) 730-1310 E-mail: pbiggins@us.medical.canon
2441 Michelle Drive, Tustin, CA 92780 PHONE: 800-421-1968 https://us.medical.canon
{4}------------------------------------------------
Image /page/4/Picture/3 description: The image shows the logo for Canon Medical Systems USA, Inc. The word "Canon" is written in a large, bold, red font. Below it, the words "CANON MEDICAL SYSTEMS USA, INC." are written in a smaller, black font.
Made For life
-
- MANUFACTURING SITE
Canon Medical Systems Corporation 1385 Shimoishigami Otawara-shi, Tochigi 324-8550, Japan
- MANUFACTURING SITE
-
- ESTABLISHMENT REGISTRATION 9614698
-
- DATE PREPARED October 2, 2020
-
- DEVICE NAME
Vantage Oran 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
-
- TRADE NAME
Vantage Oran 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
- TRADE NAME
10. CLASSIFICATION NAME
Magnetic Resonance Diagnostic Device (MRDD)
11. CLASSIFICATION PANEL
Radiology
12. DEVICE CLASSIFICATION
Class II (per 21 CFR 892.1000, Magnetic Resonance Diagnostic Device)
13. PRODUCT CODE
90-LNH
14. PREDICATE DEVICE
Predicate Device: Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR (K193097)
TABLE No. 1: Primary Predicate Device
| Subject Device | Predicate Device | |
|---|---|---|
| System | Vantage Orian 1.5T, MRT-1550, V7.0 withAiCE Reconstruction Processing Unit for MR | Vantage Orian 1.5T, MRT-1550, V6.0 withAiCE Reconstruction Processing Unit for MR |
| Marketed By | Canon Medical Systems USA, Inc. | Canon Medical Systems USA, Inc. |
| 510(k) Number | This Submission | K193097 |
| Clearance Date | July 14, 2020 |
15. REASON FOR SUBMISSION
Modification of a cleared device
2441 Michelle Drive, Tustin, CA 92780 PHONE: 800-421-1968 https://us.medical.canon
{5}------------------------------------------------
Image /page/5/Picture/3 description: The image shows the logo for Canon Medical Systems USA, Inc. The word "Canon" is in large, bold, red letters. Below it, in smaller, black letters, is the text "CANON MEDICAL SYSTEMS USA, INC."
Made For life
16. SUBMISSION TYPE
Traditional 510(k) Premarket Notification
17. DEVICE DESCRIPTION
The Vantage Orian (Model MRT-1550) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Orian uses 1.4 m short and 3.8 tons light weight magnet. It includes the Pianissimo™ technology (scan noise reduction technology). The design of the gradient coil and the WB coil of the Vantage Orian 1.5T provides the maximum field of view of 55 x 50 cm. The Model MRT-1550/AC, AD, AG, AH includes the standard gradient system and Model MRT-1550/AK, AL, AO, AP includes the XGO gradient system.
This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body. The Vantage Orian MRI System is comparable to the current 1.5T Vantage Orian MRI System (K193097), cleared July 14th, 2020 with the following modifications.
18. SUMMARY OF CHANGE(S)
This submission is to report the following software functionalities have been added:
- FASE 3D/FFE3D:
- Compressed SPEEDER 3D (Compressed Sensing 3D): This application allows acceleration O factors for shorter scan times or higher resolution in FASE3D and FFE3D in addition to FSE2D, imaging based upon the principle of compressed sensing in combination with parallel imaging.
- . FE 3D:
- FI-Quant: Data is acquired with several different and provides PDFF image, R2* image, water o image, fat image, in phase image and out of phase image (total 6 kind of images). Proton Density Fat Fraction data and R2* data is supporting fat content ratio.
- EPI
- Exsper (Expanded SPEEDER): This application allows reducing scan time for diffusion imaging. o Exsper technique scans center of k-space data but surrounding area data is undersampled. It finds the coefficient from the data of center of k-space and synthesize the undersampled data by using surrounding data and the coefficient.
- FFE 3D:
- Fast 3D for SSFP: This application allows reducing the scan time while maintaining image o quality by up to half for T1, PD, T2 weighted images and FLAIR, STIR images by adjusting data acquisition ratio.
- 3D Time-of-Flight (ToF):
- Fast 3D for TOF: This application allows reducing the scan time while maintaining image quality o by up to half for TOF images by adjusting data acquisition ratio.
- Short T2* map (multi echo-UTE): UTE Imaging is available for acquisition of different TE data for ● T2* mapping of tissues with short T2*.
2441 Michelle Drive, Tustin, CA 92780 PHONE: 800-421-1968 https://us.medical.canon
{6}------------------------------------------------
Image /page/6/Picture/3 description: The image shows the logo for Canon Medical Systems USA, Inc. The word "Canon" is in large, red, bold letters. Below it, the words "CANON MEDICAL SYSTEMS USA, INC." are in smaller, black letters.
Made For life
- . Advanced DWI-Diffusion time: Various diffusion times are available
- . AiCE noise estimation improvement: By taking into consideration g-factor, noise can be removed from the part where g-factor was considered.
19. SAFETY PARAMETERS
| Item | Subject Device:Vantage Orian 1.5T, MRT-1550, V7.0with AiCE Reconstruction ProcessingUnit for MR | Predicate Device:Vantage Orian 1.5T, MRT-1550, V6.0with AiCE Reconstruction ProcessingUnit for MR | Notes |
|---|---|---|---|
| Static field strength | 1.5T | 1.5T | Same |
| Operational Modes | Normal and 1st Operating Mode | Normal and 1st Operating Mode | Same |
| i. Safety parameterdisplay | SAR, dB/dt | SAR, dB/dt | Same |
| ii. Operating modeaccess requirements | Allows screen access to 1st leveloperating mode | Allows screen access to 1st leveloperating mode | Same |
| Maximum SAR | 4W/kg for whole body (1st operatingmode specified in IEC 60601-2-33:2010+A1:2013+A2:2015) | 4W/kg for whole body (1st operatingmode specified in IEC 60601-2-33:2010+A1:2013+A2:2015) | Same |
| Maximum dB/dt | 1st operating mode specified in IEC60601-2-33:2010+A1:2013+A2:2015 | 1st operating mode specified in IEC60601-2-33:2010+A1:2013+A2:2015 | Same |
| Potential emergencycondition and meansprovided for shutdown | Shutdown by Emergency Ramp DownUnit for collision hazard forferromagnetic objects | Shutdown by Emergency Ramp DownUnit for collision hazard forferromagnetic objects | Same |
20. IMAGING PERFORMANCE PARAMETERS
No change from the previous predicate submission, K193097.
21. INDICATIONS FOR USE
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces crosssectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
- Proton density (PD) (also called hydrogen density) ●
- Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2) ●
- Flow dynamics
- Chemical Shift ●
2441 Michelle Drive, Tustin, CA 92780 PHONE: 800-421-1968 https://us.medical.canon
{7}------------------------------------------------
CAL SYSTEMS USA, INC.
Made For life
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
22. SUMMARY OF DESIGN CONTROL ACTIVITIES
Risk Management activities for new software functionalities are included in this submission. The test methods used are the same as those submitted in the previously cleared submission of the predicate device, Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR (K193097). A declaration of conformity with design controls is included in this submission.
23. SAFETY
This device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards.
This device is based upon the same technologies, materials and software as the predicate device. Risk activities were conducted in concurrence with established medical device development standards and guidance. Additionally, testing was done in accordance with applicable recognized consensus standards published by the International Electrotechnical Commission (IEC) for medical devices and the National Electrical Manufacturers Association (NEMA):
LIST OF APPLICABLE STANDARDS
- ANSI AAMI ES60601-1:2005/(R)2012 and A1:2012
- IEC60601-1-2 (2014)
- IEC60601-1-6 (2010), Amd.1 (2013)
- IEC60601-2-33 (2010), Amd.1 (2013), Amd.2 (2015)
- . IEC60825-1 (2007)
- IEC62304 (2006), Amd.1 (2015)
- IEC62366 (2007), Amd.1 (2014) ●
- NEMA MS 1 (2008)
- NEMA MS 2 (2008) ●
- NEMA MS 3 (2008)
- NEMA MS 4 (2010)
- NEMA MS 5 (2010) .
24. TESTING
Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrate that the system requirements have been met. Additionally, image quality testing was completed which demonstrated that the subject device meets predetermined acceptance criteria.
MR image quality metrics were performed, utilizing volunteer images, to assess 3D FAST sequences and 3D Compressed SPEEDER acceleration sequences. Representative images, reviewed by American Board Certified Radiologists and American Board Certified Cardiologists with MR certification, were obtained using the subject device. Reviewers provided detailed assessments of overall image noise, image sharpness, image degradation, image artifacts, diagnostic confidence, contrast, lesion/pathology conspicuity, and clinical utility. It was confirmed that 3D FAST and 3D Compressed SPEEDER images were of diagnostic quality.
Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission.
2441 Michelle Drive, Tustin, CA 92780 PHONE: 800-421-1968 https://us.medical.canon
{8}------------------------------------------------
Image /page/8/Picture/3 description: The image shows the logo for Canon Medical Systems USA, Inc. The word "Canon" is in large, bold, red letters. Below it, in smaller, black letters, is the text "CANON MEDICAL SYSTEMS USA, INC."
Made For life
25. SUBSTANTIAL EQUIVALENCE
Canon Medical Systems Corporation believes that the Vantage Orian 1.5T, MRT-1550, V7.0, Magnetic Resonance Imaging (MRI) System with AiCE Reconstruction Processing Unit for MR is substantially equivalent to the previously cleared predicate device, Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR, referenced in this submission. Canon Medical Systems Corporation believes that the changes incorporated into the Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR are substantially equivalent to the previously cleared predicate device.
26. CONCLUSION
The modifications incorporated into the Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR do not change the indications for use or the intended use of the device. Based upon bench testing, volunteer clinical imaging, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device is safe and effective for its intended use.
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.